{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:42:51Z","timestamp":1789512171249,"version":"build-2803163510"},"reference-count":46,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":191,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"BIH Charit\u00e9 Clinician Scientist"},{"name":"DFG Emmy Noether","award":["Si-1983\/4-1"],"award-info":[{"award-number":["Si-1983\/4-1"]}]},{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","award":["101040453"],"award-info":[{"award-number":["101040453"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Foundation grant within the EC3R"},{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["01EJ2206A"],"award-info":[{"award-number":["01EJ2206A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"German Research Foundation under Germany\u2019s Excellence Strategy\u2013EXC","award":["3118\/1"],"award-info":[{"award-number":["3118\/1"]}]},{"name":"German Research Foundation under Germany\u2019s Excellence Strategy\u2013EXC","award":["533770413"],"award-info":[{"award-number":["533770413"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The intestinal therapy response in patients with primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD) is not well explored. This study compared the intestinal therapy response to biological therapies in patients with PSC and IBD (PSC-IBD group) vs patients with IBD alone (IBD group).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a case\u2013control study and identified 46 patients in the PSC-IBD group and 180 in the IBD group who were treated with infliximab, vedolizumab, and\/or ustekinumab at the IBD outpatient clinic of Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus-Virchow-Klinikum. To account for differences in demographics and disease characteristics, propensity score matching (ratio 1:1) was performed. The primary outcome was clinical therapy response within 20\u2009weeks, defined as remission (partial Mayo Score \u2264 1 or Harvey-Bradshaw-Index &amp;lt; 5) or partial response (decrease of partial Mayo Score \u2265 2 or a decrease of Harvey-Bradshaw-Index &amp;gt; 3). Secondary outcomes included treatment persistence, endoscopic response, decrease in faecal calprotectin, concomitant medication and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 46 patients per group were analysed (median follow-up: PSC-IBD: 44\u2009months; IBD: 60\u2009months), with a total of 136 treatments administered. The cohort demographics and disease characteristics were balanced between both groups. While clinical response rates did not significantly differ between groups in patients receiving infliximab or vedolizumab, in patients receiving ustekinumab, clinical response rates within the first 20\u2009weeks were significantly lower in the PSC-IBD group (9 of 21, 42.9%) compared with the IBD group (20 of 26, 76.9%; P\u2009=\u20090.017). Treatment persistence after 12\u2009months of patients on biological therapy did not differ significantly between groups across all therapies, but a numerically lower persistence rate was observed for ustekinumab in the PSC-IBD group (6 of 21, 28.6%) compared with the IBD group (10 of 22, 45.5%; P\u2009=\u20090.252).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Infliximab and vedolizumab appear equally effective for achieving clinical response in patients with PSC-IBD and IBD, while the early clinical response to ustekinumab was significantly lower in patients with PSC-IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/gastro\/goag079","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T11:53:54Z","timestamp":1783598034000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world data on clinical response to inflammatory bowel disease biological treatments in patients with concurrent primary sclerosing cholangitis: a case\u2013control study"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2742-6988","authenticated-orcid":false,"given":"Robert","family":"Tosse","sequence":"first","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Maibier","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Fischer","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8442-1926","authenticated-orcid":false,"given":"Marcel","family":"Razpotnik","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8294-6673","authenticated-orcid":false,"given":"Konstantinos","family":"Kouladouros","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-0761","authenticated-orcid":false,"given":"Michael","family":"Sigal","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]},{"name":"Berlin Institute for Medical Systems Biology (BIMSB), Max Delbr\u00fcck Center for Molecular Medicine in the Helmholtz Association (MDC) , Berlin 13125,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-0416","authenticated-orcid":false,"given":"Jonas","family":"Wizenty","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Gastroenterology, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charit\u00e9 Mitte (CCM) , Berlin 13353,","place":["Germany"]},{"name":"Berlin Institute of Health at Charit\u00e9-Universit\u00e4tsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charit\u00e9 Clinician Scientist Program , Berlin 10178,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026073017102087100_goag079-B1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrgastro.2015.186","article-title":"Immunopathogenesis of IBD: current state of the art","volume":"13","author":"de Souza","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-025-01097-1","article-title":"The global burden of inflammatory bowel disease: from 2025 to 2045","volume":"22","author":"Kaplan","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B3","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2026073017102087100_goag079-B4","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"2026073017102087100_goag079-B5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1053\/j.gastro.2021.09.078","article-title":"Breaking through the therapeutic ceiling: what will it take?","volume":"162","author":"Raine","year":"2022","journal-title":"Gastroenterology"},{"key":"2026073017102087100_goag079-B6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1001\/jama.2023.15389","article-title":"Ulcerative colitis in adults: a review","volume":"330","author":"Gros","year":"2023","journal-title":"JAMA"},{"key":"2026073017102087100_goag079-B7","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15007","article-title":"Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"41","author":"Mehta","year":"2021","journal-title":"Liver Int"},{"key":"2026073017102087100_goag079-B8","doi-asserted-by":"crossref","first-page":"goag013","DOI":"10.1093\/gastro\/goag013","article-title":"Global patterns of disease progression in inflammatory bowel disease: a comprehensive synthesis of contemporary population-based cohorts","volume":"14","author":"Gros","year":"2026","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"2026073017102087100_goag079-B9","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"2026073017102087100_goag079-B10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two?","volume":"80","author":"van Munster","year":"2024","journal-title":"J Hepatol"},{"key":"2026073017102087100_goag079-B11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41572-025-00600-x","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Manns","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"2026073017102087100_goag079-B13","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1080\/14656566.2024.2407022","article-title":"Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis","volume":"25","author":"Pinnuck","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026073017102087100_goag079-B14","first-page":"e56182","article-title":"Efficacy of biologics in the treatment of primary sclerosing cholangitis associated with inflammatory bowel disease: a systematic review and meta-analysis","volume":"16","author":"Huynh","year":"2024","journal-title":"Cureus"},{"key":"2026073017102087100_goag079-B15","doi-asserted-by":"crossref","first-page":"e0347","DOI":"10.1097\/HC9.0000000000000347","article-title":"Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: a systematic review and meta-analysis","volume":"8","author":"Shah","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026073017102087100_goag079-B16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/ecco-jcc\/jjz088","article-title":"Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: a GETAID Multicentre Cohort Study","volume":"13","author":"Caron","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026073017102087100_goag079-B18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2026073017102087100_goag079-B19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B20","first-page":"A131","article-title":"P131 Efficacy and safety of advanced therapies in PSC-IBD, a single centre retrospective cohort study","volume":"73","author":"Sarras","year":"2024","journal-title":"Gut"},{"key":"2026073017102087100_goag079-B21","doi-asserted-by":"crossref","first-page":"i1916","DOI":"10.1093\/ecco-jcc\/jjae190.1213","article-title":"P1039 an evaluation of anti-IL23 therapy in primary sclerosing cholangitis associated inflammatory bowel disease","volume":"19","author":"Al-Shakhshir","year":"2025","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026073017102087100_goag079-B22","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"2026073017102087100_goag079-B23","doi-asserted-by":"crossref","first-page":"jjaf106","DOI":"10.1093\/ecco-jcc\/jjaf106","article-title":"ECCO-ESGAR-ESP-IBUS Guideline on diagnostics and monitoring of patients with inflammatory bowel disease: Part 1","volume":"19","author":"Kucharzik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026073017102087100_goag079-B24","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"key":"2026073017102087100_goag079-B25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2026073017102087100_goag079-B26","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"2026073017102087100_goag079-B27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"2026073017102087100_goag079-B28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2026073017102087100_goag079-B29","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","article-title":"From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting","volume":"24","author":"Mumolo","year":"2018","journal-title":"World J Gastroenterol"},{"key":"2026073017102087100_goag079-B30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.arthro.2021.06.037","article-title":"Best Practice guidelines for propensity score methods in medical research: consideration on theory, implementation, and reporting. a review","volume":"38","author":"Chen","year":"2022","journal-title":"Arthroscopy"},{"key":"2026073017102087100_goag079-B31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2026073017102087100_goag079-B32","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2468-1253(25)00026-3","article-title":"Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial","volume":"10","author":"Acherman","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B33","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"2026073017102087100_goag079-B34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cgh.2017.07.023","article-title":"Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon","volume":"16","author":"Krugliak Cleveland","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B35","doi-asserted-by":"crossref","first-page":"jjaf231","DOI":"10.1093\/ecco-jcc\/jjaf231.1228","article-title":"P1047 the vedolizumab clinical decision support tool does not predict treatment response in primary sclerosing cholangitis associated inflammatory bowel disease (PSC-IBD)","volume":"20","author":"Morris","year":"2026","journal-title":"J Crohn\u2019s Colitis"},{"key":"2026073017102087100_goag079-B36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0140-6736(24)01927-5","article-title":"Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies","volume":"405","author":"Rubin","year":"2025","journal-title":"Lancet"},{"key":"2026073017102087100_goag079-B37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2024.05.036","article-title":"Targeting the interleukin 23 pathway in inflammatory bowel disease","volume":"168","author":"Bourgonje","year":"2025","journal-title":"Gastroenterology"},{"key":"2026073017102087100_goag079-B38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026073017102087100_goag079-B39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41577-024-01008-6","article-title":"Strategies for targeting cytokines in inflammatory bowel disease","volume":"24","author":"Neurath","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026073017102087100_goag079-B40","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/ecco-jcc\/jjae096","article-title":"Inflammatory bowel disease associated with primary sclerosing cholangitis is associated with an altered gut microbiome and bile acid profile","volume":"18","author":"Leibovitzh","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2026073017102087100_goag079-B41","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/ecco-jcc\/jjx050","article-title":"Th1 and innate lymphoid cells accumulate in primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"11","author":"Gwela","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2026073017102087100_goag079-B42","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1056\/NEJMra1907607","article-title":"Newer biologic and small-molecule therapies for inflammatory bowel disease","volume":"385","author":"Baumgart","year":"2021","journal-title":"N Engl J Med"},{"key":"2026073017102087100_goag079-B43","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.3390\/jcm14217817","article-title":"Gut-liver axis, microbiota, bile acids, and immune response in pathogenesis of primary sclerosing cholangitis: an overview","volume":"14","author":"Fousekis","year":"2025","journal-title":"J Clin Med"},{"key":"2026073017102087100_goag079-B44","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1136\/gutjnl-2016-312354","article-title":"Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner","volume":"67","author":"Trivedi","year":"2018","journal-title":"Gut"},{"key":"2026073017102087100_goag079-B45","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00535-026-02388-3","article-title":"Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease","volume":"61","author":"Okada","year":"2026","journal-title":"J Gastroenterol"},{"key":"2026073017102087100_goag079-B46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1042\/CS20256078","article-title":"Primary bile acid shapes peripheral immunity in inflammatory bowel disease-associated primary sclerosing cholangitis","volume":"138","author":"Santos","year":"2025","journal-title":"Clin Sci (Lond)"}],"container-title":["Gastroenterology Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag079\/70399061\/goag079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/gastro\/article-pdf\/doi\/10.1093\/gastro\/goag079\/70399061\/goag079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:10:37Z","timestamp":1785445837000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/gastro\/article\/doi\/10.1093\/gastro\/goag079\/8747918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1093\/gastro\/goag079","relation":{},"ISSN":["2052-0034"],"issn-type":[{"value":"2052-0034","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"goag079"}}